Close Menu

NEW YORK- A consortium led by Vancouver, Canada-based Canexia Health (formerly Contextual Genomics) has launched a C$2,590,500 (US$1.9 million) initiative that aims to improve access to testing and treatment options for Canadian cancer patients during the coronavirus pandemic.

The initiative, named Project ACTT (Access to Cancer Testing and Treatment), will deploy a liquid biopsy test that only requires a blood draw for cancer treatment selection, eliminating the need for most patients to travel to a hospital for biopsies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.